Preclinical study results indicate that Bone Biologics’ rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. (Phylogenetic means relating to the evolutionary development and diversification of a species or group of organisms, or development and diversification of a particular feature of an organism.)
Data collected in this pilot animal study support advancement to pivotal animal study in mid-2018. Human clinical trials are slated for 2019.
Bone Biologics and UCLA are together studying the application of NELL-1 as a platform technology for use in spinal fusion, trauma and osteoporosis.
Preclinical study results indicate that Bone Biologics' rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. (Phylogenetic means relating to the evolutionary development and diversification of a species or group of organisms, or development and diversification of a particular feature of an...
Preclinical study results indicate that Bone Biologics’ rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. (Phylogenetic means relating to the evolutionary development and diversification of a species or group of organisms, or development and diversification of a particular feature of an organism.)
Data collected in this pilot animal study support advancement to pivotal animal study in mid-2018. Human clinical trials are slated for 2019.
Bone Biologics and UCLA are together studying the application of NELL-1 as a platform technology for use in spinal fusion, trauma and osteoporosis.
Copy to clipboard 
